PMID- 26821594
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20180209
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
VI  - 18
IP  - 7
DP  - 2016 Jul
TI  - Effects of intravenous iron therapy in iron-deficient patients with systolic
      heart failure: a meta-analysis of randomized controlled trials.
PG  - 786-95
LID - 10.1002/ejhf.473 [doi]
AB  - AIMS: The aim of this study was to assess the net clinical and prognostic effects
      of intravenous (i.v.) iron therapy in patients with systolic heart failure (HF)
      and iron deficiency (ID). METHODS AND RESULTS: We performed an aggregate data
      meta-analysis (random effects model) of randomized controlled trials that
      evaluated the effects of i.v. iron therapy in iron-deficient patients with
      systolic HF. We searched electronic databases up to September 2014. We identified
      five trials which fulfilled the inclusion criteria (509 patients received i.v.
      iron therapy in comparison with 342 controls). Intravenous iron therapy has been 
      shown to reduce the risk of the combined endpoint of all-cause death or
      cardiovascular hospitalization [odds ratio (OR) 0.44, 95% confidence interval
      (CI) 0.30-0.64, P < 0.0001], and the combined endpoint of cardiovascular death or
      hospitalization for worsening HF (OR 0.39, 95% CI 0.24-0.63, P = 0.0001).
      Intravenous iron therapy resulted in a reduction in NYHA class (data are reported
      as a mean net effect with 95% CIs for all continuous variables) (-0.54 class, 95%
      CI -0.87 to -0.21, P = 0.001); an increase in 6-min walking test distance (+31 m,
      95% CI 18-43, P < 0.0001); and an improvement in quality of life [Kansas City
      Cardiomyopathy Questionnaire (KCCQ) score +5.5 points, 95% CI 2.8-8.3, P <
      0.0001; European Quality of Life-5 Dimensions (EQ-5D) score +4.1 points, 95% CI
      0.8-7.3, P = 0.01; Minnesota Living With Heart Failure Questionnaire (MLHFQ)
      score -19 points, 95% CI:-23 to -16, P < 0.0001; and Patient Global Assessment
      (PGA) +0.70 points, 95% CI 0.31-1.09, P = 0004]. CONCLUSION: The evidence
      indicates that i.v. iron therapy in iron-deficient patients with systolic HF
      improves outcomes, exercise capacity, and quality of life, and alleviates HF
      symptoms.
CI  - (c) 2016 The Authors. European Journal of Heart Failure (c) 2016 European Society
      of Cardiology.
FAU - Jankowska, Ewa A
AU  - Jankowska EA
AD  - Laboratory for Applied Research on Cardiovascular System, Department of Heart
      Diseases, Wroclaw Medical University, Wroclaw, Poland.
AD  - Cardiology Department, Centre for Heart Diseases, Military Hospital, Wroclaw,
      Poland.
FAU - Tkaczyszyn, Michal
AU  - Tkaczyszyn M
AD  - Laboratory for Applied Research on Cardiovascular System, Department of Heart
      Diseases, Wroclaw Medical University, Wroclaw, Poland.
AD  - Cardiology Department, Centre for Heart Diseases, Military Hospital, Wroclaw,
      Poland.
FAU - Suchocki, Tomasz
AU  - Suchocki T
AD  - Biostatistics Group, Department of Genetics, Wroclaw University of Environmental 
      and Life Sciences, Wroclaw, Poland.
FAU - Drozd, Marcin
AU  - Drozd M
AD  - Laboratory for Applied Research on Cardiovascular System, Department of Heart
      Diseases, Wroclaw Medical University, Wroclaw, Poland.
AD  - Cardiology Department, Centre for Heart Diseases, Military Hospital, Wroclaw,
      Poland.
FAU - von Haehling, Stephan
AU  - von Haehling S
AD  - Division of Innovative Clinical Trials, Department of Cardiology & Pulmonology,
      University Medicine Gottingen (UMG), Gottingen, Germany.
FAU - Doehner, Wolfram
AU  - Doehner W
AD  - Department of Cardiology, Virchow Klinikum, Charite - Universitatsmedizin,
      Berlin, Germany.
AD  - Center for Stroke Research Berlin, Charite - Universitatsmedizin, Berlin,
      Germany.
FAU - Banasiak, Waldemar
AU  - Banasiak W
AD  - Cardiology Department, Centre for Heart Diseases, Military Hospital, Wroclaw,
      Poland.
FAU - Filippatos, Gerasimos
AU  - Filippatos G
AD  - Heart Failure Unit, Department of Cardiology, Athens University Hospital Attikon,
      Athens, Greece.
FAU - Anker, Stefan D
AU  - Anker SD
AD  - Division of Innovative Clinical Trials, Department of Cardiology & Pulmonology,
      University Medicine Gottingen (UMG), Gottingen, Germany.
FAU - Ponikowski, Piotr
AU  - Ponikowski P
AD  - Cardiology Department, Centre for Heart Diseases, Military Hospital, Wroclaw,
      Poland.
AD  - Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Research Support, Non-U.S. Gov't
DEP - 20160128
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Trace Elements)
RN  - E1UOL152H7 (Iron)
SB  - IM
CIN - Eur J Heart Fail. 2016 Jul;18(7):796-7. PMID: 27412574
MH  - Administration, Intravenous
MH  - Cardiovascular Diseases/mortality
MH  - Cause of Death
MH  - Deficiency Diseases/complications/*drug therapy
MH  - Disease Progression
MH  - Exercise Tolerance
MH  - Heart Failure, Systolic/*complications
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Iron/deficiency/*therapeutic use
MH  - Mortality
MH  - Odds Ratio
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Trace Elements/*therapeutic use
MH  - Walk Test
OTO - NOTNLM
OT  - *Anaemia
OT  - *Heart failure
OT  - *Intravenous iron
OT  - *Iron deficiency
OT  - *Meta-analysis
OT  - *Outcomes
EDAT- 2016/01/30 06:00
MHDA- 2017/11/01 06:00
CRDT- 2016/01/30 06:00
PHST- 2015/08/27 00:00 [received]
PHST- 2015/11/06 00:00 [revised]
PHST- 2015/12/06 00:00 [accepted]
PHST- 2016/01/30 06:00 [entrez]
PHST- 2016/01/30 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
AID - 10.1002/ejhf.473 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2016 Jul;18(7):786-95. doi: 10.1002/ejhf.473. Epub 2016 Jan 28.